Source: ChinaBio Today

Lee's Pharm: Lee's Pharma to File for China Approval of PD-L1 Under Breakthrough Rules

China Oncology Focus (COF), a subsidiary of Hong Kong-based Lee's Pharma, reported that its anti-PD-L1 antibody, socazolimab, was granted breakthrough therapy status in China. Lee's said it plans to file a China NDA for socazolimab as a cervical cancer therapy in Q2 2021. In 2014, Lee's acquired China rights to the candidate from San Diego's Sorrento Therapeutics in a deal worth over $50 million. The two companies are currently in talks about partnering additional Sorrento antibodies. More details.... Stock Symbols: (HK: 950) (NSDQ: SRNE) Share this with colleagues:

Read full article »
Est. Annual Revenue
$5.0-25M
Agree?
Est. Employees
1-25
Agree?
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100



Lee's Pharm is a Private company. Lee's Pharm generates $1M in revenue per employee Lee's Pharm has 2 followers on Owler.